| Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call Transcript |
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q2 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Vincent Anzalone - Vice President of Investor Relations for Arrowhead Christopher Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis - SVP & Head of Global Cardio/Metabolic Franchise James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - Outgoing CFO Daniel Apel - Incoming CFO Conference Call Participants Maury Raycroft - Jefferies Jason Gerberry - Bank of America Jasmine Fels - UBS Patrick Trucchio - H.C. Wainwright & Company Luca Issi - RBC Edward Tenthoff - Piper Sandler Mike Ulz - Morgan Stanley Mayank Mamtani - B. |
seekingalpha.com |
2025-05-13 01:56:40 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: BofA Securities 2025 Health Care Conference – May 13-15, 2025 Type: Fireside Chat Presentation Date/Time: May 14, 2025, 11:20 a.m. PDT 2025 RBC Capital Markets Global Healthcare – May 20-21, 2025 Type: Fireside Chat Presentation Date/Time: May 20, 2025, 2:35 p.m. EDT Presentation webcasts may be accessed on the Events an. |
businesswire.com |
2025-05-07 11:30:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 12, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 second quarter ended March 31, 2025. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately t. |
businesswire.com |
2025-04-30 20:01:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. “Ken has been a valuable member of the Arrowhea. |
businesswire.com |
2025-04-15 20:00:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on April 3, 2025, the Company's Board of Directors approved “inducement” grants to 21 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 34,190 restricted stock units. The grants are outside the Company's stockholder-approved equity incentive plans and vest. |
businesswire.com |
2025-04-04 20:30:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Is Finally Arriving |
Arrowhead Pharmaceuticals, Inc. has streamlined its focus, now boasting 19 clinical programs, including 4 phase 3 trials and 4 phase 2 trials. Plozasiran shows superior results in triglyceride reduction and dosing frequency compared to its main competitor, Olezarsen, with a pivotal PDUFA date on November 18. ARWR's strong financial position is bolstered by a recent deal with Sarepta, extending its cash runway into 2028. |
seekingalpha.com |
2025-03-21 19:56:13 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company's investigational RNA interference (RNAi) therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. The company plans to present additional results at a medical meeting in 2025. Select Phase 1/2 Study Results Patients with IgA nephrop. |
businesswire.com |
2025-03-10 09:30:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of two first-in-class clinical stage, RNAi-based investigational therapeutics being developed for the treatment of obesity and metabolic diseases. The two candidates, ARO-INHBE and ARO-ALK7, have the potential to reduce body weight and fat mass with a novel mechanism of action that may lead to improved preservation of lean muscle mass comp. |
businesswire.com |
2025-03-06 10:45:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) marks Rare Disease Day with the expansion of the We'll Get There Soon campaign, initially launched for healthcare providers in November 2024. This new phase introduces a dedicated educational website, www.LowerMyTGs.com, and the Spotlight on FCS white paper, which provides essential resources and support for those affected by Familial Chylomicronemia Syndrome (FCS). FCS is an ultra-rare genetic disorder that signi. |
businesswire.com |
2025-02-28 11:00:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like kinase 7 (ALK7) being developed as a potential treatment for obesity. The results were presented in a poster at the Keystone Symposia on Obesity and Adipose Tissue held February 23–26, 2025 in Banff, AB, Canada. ARO-ALK7 is the first RNAi-based therapy to directly targe. |
businesswire.com |
2025-02-25 09:30:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions |
Arrowhead Pharmaceuticals is executing on the clinical and regulatory side during adverse market conditions for biotech companies and genetic stocks in particular. Zodasiran is back in the clinic with a phase 3 trial plan in homozygous familiar hypercholesterolemia patients. We could see as many as three phase 1/2 readouts this year from programs that were recently partnered with Sarepta, and ARO-DM1 program milestones point to registrational intent. |
seekingalpha.com |
2025-02-19 13:53:04 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript |
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Company Participants Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis - SVP & Head of Global Cardio/Metabolic Franchise James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - CFO Conference Call Participants Luca Issi - RBC Capital David Lebowitz - Citi Jasmine Fels - UBS Maury Raycroft - Jefferies Edward Tenthoff - PSC Patrick Trucchio - H.C. Wainwright Mayank Mamtani - B. |
seekingalpha.com |
2025-02-10 23:35:25 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, 2025, at 4:30 p.m. ET to discuss the results. “During the recent period, Arrowhead signed and closed a potentially transformational licensing and collaboration agreement with Sarepta Therapeutics and submitted our first NDA for investigational plozasiran, which w. |
businesswire.com |
2025-02-10 18:01:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT) announced on November 26, 2024, has now closed. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions. Summary Financial Terms Upon closing, Arrowhead receives a $500 milli. |
businesswire.com |
2025-02-10 10:30:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 first quarter ended December 31, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approxim. |
businesswire.com |
2025-01-22 18:00:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a severe and rare genetic disease. The FDA provided a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, and indicated it is not currently planning to hold an advisory committee meeting. Arrowh. |
businesswire.com |
2025-01-17 18:30:00 |
Czytaj oryginał (ang.) |
| Sarepta's Elevidys launch remains strong with solid beat, says JPMorgan |
Sarepta + Arrowhead +0.18 (+0.97%) |
https://thefly.com |
2025-01-13 17:00:25 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. Arrowhead also filed recently a request for regulatory clearance to initiate a clinical trial for its second obesity candidate, ARO-ALK7. Both ARO-INHBE and ARO-ALK7 are designed to intervene in a kn. |
businesswire.com |
2024-12-23 09:30:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 13, 2024, the Company's Board of Directors approved “inducement” grants to 20 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 44,350 restricted stock units. The grants are outside the Company's stockholder-approved equity incentive plans and v. |
businesswire.com |
2024-12-19 18:59:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company's investigational RNA interference (RNAi) therapeutic targeting complement factor B being developed as a potential treatment for complement mediated diseases. The data were presented today, December 11, 2024, at the 8th Complement-Based Drug Development Summit being held in Boston. “Dysregulated activation of the complement sy. |
businesswire.com |
2024-12-11 09:30:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7, the company's second investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. ARO-ALK7 is the first RNAi-based therapy to directly target a gene expressed in adipose tissue and highlights Arrowhead's leadership in the delivery of siRNA to multipl. |
businesswire.com |
2024-12-03 09:30:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Sandler 36th Annual Healthcare Conference – December 3-5, 2024 Type: Fireside Chat Presentation Date/Time: December 3, 2024, 1:30 p.m. EST 7th Annual Evercore ISI HealthCONx Conference – December 3-5, 2024 Type: Fireside Chat Presentation Date/Time: December 4, 2024, 2:10 p.m. EST The APA/JPS/CAP/IAP 2024 Joint Meeting – De. |
businesswire.com |
2024-12-02 09:30:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2024 Earnings Call Transcript |
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q4 2024 Earnings Conference Call November 26, 2024 4:30 PM ET Company Participants Vince Anzalone - VP, IR Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis - SVP & Head of Global Cardiometabolic Franchise James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - CFO Conference Call Participants Jasmine Fels - UBS Luca Issi - RBC Capital Andrea Newkirk - Goldman Sachs Maury Raycroft - Jefferies Dina Ramadane - Bank of America Patrick Trucchio - H.C. Wainwright Edward Tenthoff - PSC Mayank Mamtani - B. |
seekingalpha.com |
2024-11-27 01:08:49 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference call today, November 26, 2024, at 4:30 p.m. ET to discuss the results. “Arrowhead is well positioned, both individually and with partners, to advance and ultimately commercialize important new medicines using our proprietary TRiM™ technology. We have the potential to impact the lives of millions. |
businesswire.com |
2024-11-26 18:00:00 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR). Sarepta will obtain exclusive global rights to multiple clinical, preclinical, and discovery-stage programs for rare, genetic diseases of the muscle, central nervous system (CNS), and the lungs. The agreement will add meaningfully to S. |
businesswire.com |
2024-11-26 09:00:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a severe and rare genetic disease which currently has no FDA approved treatments. Arrowhead also intends to submit applications for approval of investigational plozasiran for the treatment of patients with FCS to a. |
businesswire.com |
2024-11-18 09:31:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and SHASTA-2 studies of investigational plozasiran. These data were presented in two oral presentations at the American Heart Association Scientific Sessions 2024 (AHA24) and PALISADE data was simultaneously published in the AHA journal, Circulation. “In the Phase 3 PALISADE study in patients with and wit. |
businesswire.com |
2024-11-18 09:30:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 15th Annual American Conference on Pharmacometrics (ACoP 2024) – November 10-13, 2024 Title: Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemia Presenter: Jack Shi Session: Poster Title: Population K-PD Modeling of Plozasiran (ARO-APOC3), a. |
businesswire.com |
2024-11-04 09:30:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We'll Get There Soon,' to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today, on FCS Awareness Day, announced the launch of a new disease awareness campaign, 'We'll Get There Soon,' to bring hope to the rare disease community affected by Familial Chylomicronemia Syndrome (FCS). The campaign seeks to raise awareness about FCS, a severe and rare condition marked by persistently high triglyceride levels despite standard treatment, which can lead to serious and potentially life-threateni. |
businesswire.com |
2024-11-01 09:30:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 11, 2024, the Company's Board of Directors approved “inducement” grants to 34 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 66,750 restricted stock units. The grants are outside the Company's stockholder-approved equity incentive plans and ve. |
businesswire.com |
2024-10-14 20:30:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-INHBE, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. Arrowhead also plans to file for regulatory clearance before the end of 2024 to initiate a clinical trial for its second obesity candidate, ARO-ALK7. “Arrowhead's two investigational R. |
businesswire.com |
2024-09-23 11:30:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug |
Shares of Arrowhead Pharmaceuticals (ARWR) gained Tuesday after the biotech firm announced positive results in a late-stage study of its experimental treatment for a rare metabolic disorder, and said it plans to request regulatory approval to market it. |
investopedia.com |
2024-09-03 15:01:26 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 3 PALISADE study of investigational plozasiran in patients with familial chylomicronemia syndrome (FCS), a severe and rare genetic disease which currently has no approved treatments in the U.S. PALISADE successfully met its primary endpoint and all multiplicity-controlled key secondary endpoints, including statistically significant reductions in triglycerides (TGs), apolipopr. |
businesswire.com |
2024-09-02 10:36:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals, Inc. (ARWR) 2024 Summer Series R&D Webinar: Obesity/Metabolic - ARO-INHBE Conference (Transcript) |
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) 2024 Summer Series R&D Webinar: Obesity/Metabolic - ARO-INHBE Conference August 14, 2024 2:00 PM ET Company Participants Vincent Anzalone - Vice President and Head of Investor Relations Dr. Carel Le Roux - Chair of Metabolic Medicine, University College Dublin Erik Bush - Senior Vice President, Biology Tao Pei - Senior Vice President, Discovery Chemistry James Hamilton - SVP, Discovery and Translational Medicine Operator Good afternoon, and welcome to the Arrowhead Summer Series of R&D Webinars Part 4. As a reminder, all participants are in a listen-only mode. |
seekingalpha.com |
2024-08-14 22:59:09 |
Czytaj oryginał (ang.) |
| Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025 |
Low-priced stocks to buy with the potential to double within the next year or so have inherent appeal for investors. Individual shares are affordable making it relatively easy to establish a stake. |
investorplace.com |
2024-06-28 10:50:00 |
Czytaj oryginał (ang.) |
| Canva Upskills 70 Million Educators and Students Globally with New Teacher Certification Course |
SYDNEY--(BUSINESS WIRE)--Canva, the world's leading visual communication platform, continues to experience significant growth in its global K-12 and higher education user base, adding 40 million users in the past year alone. With 70 million teachers and students now onboard, comprising nearly half of Canva's total users, this growth is driven by AI integration and visual communication adoption across prominent institutions like the University of California, New York City Public Schools, and the. |
businesswire.com |
2024-06-25 18:01:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced plans to advance investigational plozasiran into a Phase 3 cardiovascular outcomes trial called CAPITAN. This comes after promising results were recently announced from multiple clinical trials in three distinct patient populations, including the pivotal Phase 3 PALISADE study in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), the Phase 2 SHASTA-. |
businesswire.com |
2024-06-25 17:55:00 |
Czytaj oryginał (ang.) |